1 of 1
Story summary
- China's biopharmaceutical sector has entered an 'innovation 2.0' phase and could surpass global competitors, including the United States.
- A Clarivate report says Chinese firms now prioritize value-driven development over rapid expansion.
- Alice Zeng of Clarivate notes China's past focus was on R&D processes rather than post-approval outcomes.
- The United States has restricted federal contracts with Chinese firms, but these restrictions may yield diminishing returns as Chinese drug innovation grows.
